This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled “The Role of Endpoint Adjudication in Medical Device Clinical Trials”. The think tank was cosponsored by the Cardiac Safety Research Committee, MDEpiNet and the US Food and Drug Administration (FDA) and was convened at the FDA's White Oak headquarters on March 11, 2016. Attention was focused on tailoring best practices for evaluation of endpoints in medical device clinical trials, practical issues in endpoint adjudication of therapeutic, diagnostic, biomarker and drug-device combinations, and the role of adjudication in regulatory and reimbursement issues throughout the device lifecycle. Attendees included representatives from medical device companies, the FDA, Centers for Medicare and Medicaid Services (CMS), end point adjudication specialist groups, clinical research organizations, and active, academically based adjudicators. The manuscript presents recommendations from the think tank regarding (1) rationale for when adjudication is appropriate, (2) best practices establishment and operation of a medical device adjudication committee and (3) the role of endpoint adjudication for post market evaluation in the emerging era of real world evidence. (Am Heart J 2017;190:76-85.)
Recent Insights
»
Whitepapers
»
Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing ev
Most Recent Flipbooks
Save the Data. Protect the Patients. Prepare for What Comes Next: Remote Clinical Research Coordinators
Clinical Research Trends & Insights for 2020
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.

The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design

Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk

Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials

Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines

Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting

Part 4: Planning for Recovery: How Research Sponsors and Research Sites are Thinking Ahead to Restart Research